Adaptimmune Therapeutics Plc Share Price (NASDAQ: ADAP)

$0.06

Live

Last updated on August 23, 2025 at 12:37 AM IST

$₹

Check the interactive Adaptimmune Therapeutics Plc Stock chart to analyse performance

Adaptimmune Therapeutics Plc stock performance

as on August 23, 2025 at 12:37 AM IST

Today's Low:$0.06
Today's High:$0.06
$0.06
6.67%
Downside
Day's Volatility :6.67%
Upside
0.0%
52 Weeks Low:$0.05
52 Weeks High:$1.33
$0.06
13.33%
Downside
52 Weeks Volatility :96.09%
Upside
95.49%

Adaptimmune Therapeutics Plc Stock Returns

Period	Adaptimmune Therapeutics Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-78.69%	5.0%	0.0%
6 Months	-89.33%	-6.4%	0.0%
1 Year	-94.9%	-11.5%	0.0%
3 Years	-97.25%	4.5%	-7.7%

Adaptimmune Therapeutics Plc Key Stats

Check Adaptimmune Therapeutics Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.06
Open	$0.055
Today's High	$0.06
Today's Low	$0.0551
Market Capitalization	$15.1M
Today's Volume	$25.4M
52 Week High	$1.33
52 Week Low	$0.052
Revenue TTM	$65.1M
EBITDA	$-137.2M
Earnings Per Share (EPS)	$-0.66
Profit Margin	-260.82%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1341.1%

Stock Returns calculator for Adaptimmune Therapeutics Plc Stock including INR - Dollar returns

The Adaptimmune Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Adaptimmune Therapeutics Plc investment value today

Current value as on today

₹9,409

Returns

₹90,591

(-90.59%)

Returns from Adaptimmune Therapeutics Plc Stock

₹94,872 (-94.87%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Adaptimmune Therapeutics Plc Stock

6825.0%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Investment in Adaptimmune Therapeutics Plc Shares from India has grown by 6825.0% over the past 30 days, indicating increased transactional activity.

1294%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Adaptimmune Therapeutics Plc Stock from India on INDmoney has increased by 1294% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Adaptimmune Therapeutics Plc

Name
Holdings %
Name
Holdings %
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management, LLC
8.96%
Two Seas Capital LP
7.75%
NEA Management Company, LLC
6.44%
Mpm Asset Management, LLC
2.01%
MPM Oncology Impact Management LP
1.85%

Analyst Recommendation on Adaptimmune Therapeutics Plc Stock

Rating

Trend

Buy

69%Buy

23%Hold

7%Sell

Based on 13 Wall street analysts offering stock ratings for Adaptimmune Therapeutics Plc(by analysts ranked 0 to 5 stars)

Adaptimmune Therapeutics Plc Share Price Target

What analysts predicted

Upside of 962.5%

Target:

$0.64

Current:

$0.06

Adaptimmune Therapeutics Plc share price target is $0.64, a slight Upside of 962.5% compared to current price of $0.06 as per analysts' prediction.

Adaptimmune Therapeutics Plc Stock Insights

Price Movement
In the last 1 month, ADAP stock has moved down by -78.1%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.22M → 13.67M (in $), with an average increase of 51.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -74.21M → -30.34M (in $), with an average increase of 56.4% per quarter
ADAP vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 163.2%
ADAP vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 114.2% return, outperforming this stock by 211.4%
Price to Sales
ForADAP every $1 of sales, investors are willing to pay $0.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.6 for every $1 of sales.

Adaptimmune Therapeutics Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.1M	↓ 98.11%
Net Income	$-137.2M	↑ 43.61%
Net Profit Margin	-12.2K%	↓ 12064.53%

	FY20	Y/Y Change
Revenue	$4.0M	↑ 252.76%
Net Income	$-130.1M	↓ 5.16%
Net Profit Margin	-3.3K%	↑ 8938.23%

	FY21	Y/Y Change
Revenue	$6.1M	↑ 55.36%
Net Income	$-158.1M	↑ 21.52%
Net Profit Margin	-2.6K%	↑ 715.82%

	FY22	Y/Y Change
Revenue	$27.1M	↑ 341.5%
Net Income	$-165.5M	↑ 4.66%
Net Profit Margin	-609.46%	↑ 1961.53%

	FY23	Y/Y Change
Revenue	$60.3M	↑ 122.05%
Net Income	$-113.9M	↓ 31.18%
Net Profit Margin	-188.9%	↑ 420.56%

	FY24	Y/Y Change
Revenue	$178.0M	↑ 195.34%
Net Income	$-70.8M	↓ 37.81%
Net Profit Margin	-39.78%	↑ 149.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$5.7M	↑ 2336.82%
Net Income	$-48.5M	↑ 0.35%
Net Profit Margin	-854.23%	↑ 19889.1%

	Q2 FY24	Q/Q Change
Revenue	$128.2M	↑ 2158.38%
Net Income	$69.5M	↓ 243.33%
Net Profit Margin	54.22%	↑ 908.45%

	Q3 FY24	Q/Q Change
Revenue	$40.9M	↓ 68.1%
Net Income	$-17.6M	↓ 125.34%
Net Profit Margin	-43.07%	↓ 97.29%

	Q4 FY24	Q/Q Change
Revenue	$3.2M	↓ 92.12%
Net Income	$-74.2M	↑ 321.27%
Net Profit Margin	-2.3K%	↓ 2260.31%

	Q1 FY25	Q/Q Change
Revenue	$7.3M	↑ 126.1%
Net Income	$-47.6M	↓ 35.88%
Net Profit Margin	-653.18%	↑ 1650.2%

	Q2 FY25	Q/Q Change
Revenue	$13.7M	↑ 87.74%
Net Income	$-30.3M	↓ 36.24%
Net Profit Margin	-221.83%	↑ 431.35%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-96.4M	↓ 261.97%

	FY20	Y/Y Change
Profit	$-87.6M	↓ 9.1%

	FY21	Y/Y Change
Profit	$-104.9M	↑ 19.78%

	FY22	Y/Y Change
Profit	$-100.6M	↓ 4.16%

	FY23	Y/Y Change
Profit	$50.4M	↓ 150.13%

	FY24	Y/Y Change
Profit	$178.0M	↑ 252.93%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.8M	↓ 207.87%

	Q2 FY24	Q/Q Change
Profit	$125.6M	↑ 4308.65%

	Q3 FY24	Q/Q Change
Profit	$40.9M	↓ 67.44%

	Q4 FY24	Q/Q Change
Profit	$3.2M	↓ 92.12%

	Q1 FY25	Q/Q Change
Profit	$6.4M	↑ 98.82%

	Q2 FY25	Q/Q Change
Profit	$11.2M	↑ 74.46%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-112.5M	↑ 7.78%
Investing Cash Flow	$94.9M	↓ 643.88%
Financing Cash Flow	$366.0K	↓ 99.64%

	FY20	Y/Y Change
Operating Cash Flow	$-53.6M	↓ 52.37%
Investing Cash Flow	$-278.9M	↓ 393.77%
Financing Cash Flow	$340.1M	↑ 92810.11%

	FY21	Y/Y Change
Operating Cash Flow	$10.7M	↓ 120.02%
Investing Cash Flow	$75.8M	↓ 127.18%
Financing Cash Flow	$3.3M	↓ 99.03%

	FY22	Y/Y Change
Operating Cash Flow	$-141.8M	↓ 1421.36%
Investing Cash Flow	$89.1M	↑ 17.59%
Financing Cash Flow	$12.9M	↑ 291.33%

	FY23	Y/Y Change
Operating Cash Flow	$-140.9M	↓ 0.63%
Investing Cash Flow	$176.5M	↑ 98.05%
Financing Cash Flow	$880.0K	↓ 93.16%

	FY24	Y/Y Change
Operating Cash Flow	$-73.2M	↓ 48.04%
Investing Cash Flow	$-59.0M	↓ 133.39%
Financing Cash Flow	$78.7M	↑ 8848.75%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-31.9M	↑ 117.58%
Investing Cash Flow	$-357.8K	↓ 100.52%
Financing Cash Flow	$29.2M	↑ 39384.2%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$47.4M	↓ 248.4%
Investing Cash Flow	$-743.0K	↑ 107.66%
Financing Cash Flow	$24.5M	↓ 16.11%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-54.5M	↓ 214.91%
Investing Cash Flow	$-66.0M	↑ 8785.33%
Financing Cash Flow	$25.0M	↑ 1.99%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-34.2M	↓ 37.18%
Investing Cash Flow	$8.2M	↓ 112.37%
Financing Cash Flow	$1000.0	↓ 100.0%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-66.6M	↑ 94.69%
Investing Cash Flow	$41.2M	↑ 403.91%
Financing Cash Flow	$-25.3M	↓ 2532100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-34.8M	↓ 47.77%
Investing Cash Flow	$18.5M	↓ 55.07%
Financing Cash Flow	$1.7M	↓ 106.53%

Adaptimmune Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Adaptimmune Therapeutics Plc is currently in a neutral trading position according to technical analysis indicators.

Adaptimmune Therapeutics Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adaptimmune Therapeutics Plc	-79.41%	-89.33%	-94.9%	-97.25%	-99.28%
Regeneron Pharmaceuticals, Inc.	4.5%	-14.59%	-49.64%	-0.73%	0.56%
Beone Medicines Ltd	6.48%	22.93%	60.47%	81.44%	32.24%
Vertex Pharmaceuticals Incorporated	-16.69%	-17.94%	-17.2%	38.81%	48.58%
Alnylam Pharmaceuticals, Inc.	43.34%	86.27%	68.31%	115.22%	254.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adaptimmune Therapeutics Plc	NA	NA	0.11	-0.47	-13.41	-0.41	NA	-0.27
Regeneron Pharmaceuticals, Inc.	14.9	14.9	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.01	28.01	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adaptimmune Therapeutics Plc	Buy	$15.1M	-99.28%	NA	-260.82%
Regeneron Pharmaceuticals, Inc.	Buy	$62.6B	0.56%	14.9	31.37%
Beone Medicines Ltd	NA	$37.6B	32.24%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.1B	48.58%	28.01	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	254.29%	NA	-12.96%

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Organization	Adaptimmune Therapeutics Plc
Employees	506
CEO	Mr. Adrian G. Rawcliffe
Industry	Health Technology

Key Management of Adaptimmune Therapeutics Plc

Name	Title
Mr. Adrian G. Rawcliffe	CEO & Director
Mr. William C. A. Bertrand Jr., Esq., J.D.	COO & Chief Compliance Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.	Co-Founder
Ms. Joanna Brewer Ph.D.	Chief Scientific Officer
Dr. Juli P. Miller Ph.D.	VP of Corporate Affairs & Investor Relations
Ms. Kerry Sharp	Senior VP & General Counsel
Ms. Dana Lynch	Senior Director of Corporate Communications
Mr. John Lunger	Chief Patient Supply Officer
Mr. Dennis Williams Pharm.D.	Senior Vice President of Late Stage Development
Ms. Margaret Henry	Corporate Secretary

Important FAQs about investing in ADAP Stock from India :

What is Adaptimmune Therapeutics Plc share price today?

Adaptimmune Therapeutics Plc share price today is $0.06 as on August 23, 2025 at 12:37 AM IST. Adaptimmune Therapeutics Plc share today touched a day high of $0.06 and a low of $0.06.

What is the 52 week high and 52 week low for Adaptimmune Therapeutics Plc share?

Adaptimmune Therapeutics Plc share touched a 52 week high of $1.33 and a 52 week low of $0.05. Adaptimmune Therapeutics Plc stock price today i.e. August 23, 2025 at 12:37 AM IST is trending at $0.06, lower by 95.49% versus the 52 week high.

How to invest in Adaptimmune Therapeutics Plc Stock (ADAP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Adaptimmune Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Adaptimmune Therapeutics Plc Shares that will get you 25.0000 shares as per Adaptimmune Therapeutics Plc share price of $0.06 per share as on August 23, 2025 at 12:37 AM IST.

What is the minimum amount required to buy Adaptimmune Therapeutics Plc Stock (ADAP) from India?

Indian investors can start investing in Adaptimmune Therapeutics Plc (ADAP) shares with as little as ₹87.521 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Adaptimmune Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Adaptimmune Therapeutics Plc share’s latest price of $0.06 as on August 23, 2025 at 12:37 AM IST, you will get 166.6667 shares of Adaptimmune Therapeutics Plc. Learn more about fractional shares .

What are the returns that Adaptimmune Therapeutics Plc has given to Indian investors in the last 5 years?

Adaptimmune Therapeutics Plc stock has given -99.28% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?